Answers are grounded in this paper and cite their sources.
INTRODUCTION: Pembrolizumab or durvalumab plus gemcitabine and cisplatin is a first-line option for unresectable or metastatic biliary tract cancer. KEYNOTE-966 and TOPAZ-1 demonstrated improved overall survival, with similar rates of severe treatment-related adverse events compared with chemotherapy alone. However, biliary obstruction, cholangitis, stents, hepatic and renal dysfunction, frailty and polypharmacy complicate treatment delivery and adverse-event attribution. Distinguishing treatment toxicity from disease-related complications is therefore important when assessing clinical deterioration and making decisions about treatment interruption or resumption. AREAS COVERED: This narrative review examines drug-specific and overlapping toxicities, organ-system adverse events, drug-drug interactions, supportive medications, special populations, biliary stent management and pharmacovigilance needs. Treatment interruption, chemotherapy dose modification and diagnostic uncertainty are also discussed. Evidence was identified through PubMed and Embase searches covering January 2010 to September 2026. EXPERT OPINION: Available evidence does not establish a safety advantage for either checkpoint inhibitor. The opportunity to continue gemcitabine beyond eight cycles in KEYNOTE-966 makes cumulative chemotherapy exposure a practical consideration, but does not prove greater toxicity caused by pembrolizumab. Management depends on identifying the likely cause and deciding whether biliary intervention, corticosteroids or chemotherapy dose adjustment is appropriate. Evidence remains limited for patients with persistent cholestasis, poor performance status or frailty.
No takes yet. Share an insight, caveat, or question.
Erul et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: